NeuralStem Inc. ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data at the Neuro Diabetes Medical Symposium in Romania
5/20/2013 9:52:10 AM
More...
|
NeuralStem Inc. CEO, Richard Garr, to Present at Annual World Stem Cells and Regenerative Medicine Congress In London
5/16/2013 10:21:46 AM
More...
|
NeuralStem Inc. Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data at the Romanian Neurological Society Congress
5/13/2013 7:53:35 AM
More...
|
NeuralStem Inc. Reports First Quarter Financial Results and Provides Business and Clinical Update
5/13/2013 6:19:53 AM
More...
|
NeuralStem Inc. ALS Trial Investigator and Patient on Sirius XM
5/9/2013 9:23:47 AM
More...
|
NeuralStem Inc. ALS Trial Data Presented at the American Association of Neurological Surgeons Annual Meeting
4/29/2013 10:19:27 AM
More...
|
NeuralStem Inc. and the National Football League Alumni Association Announce Initiative on Brain Injury Treatment
4/25/2013 9:56:38 AM
More...
|
FDA Approves NeuralStem Inc. to Treat Final Cohort in NSI-189 Phase Ib Trial in Major Depressive Disorder
4/22/2013 11:15:19 AM
More...
|
NeuralStem Inc. CEO, Richard Garr, to Participate in Traumatic Brain Injury Panel at Biotechnology Industry Organization (BIO) International Convention
4/18/2013 11:08:07 AM
More...
|
NeuralStem Inc. Receives FDA Approval to Commence Phase II Stem Cell Trial in Amytrophic Lateral Sclerosis
4/17/2013 9:44:27 AM
More...
|
|